Stock Analysis of Lyra Therapeutics Inc (LYRA) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code LYRA
Close 0.328
Change -0.0036 / 1.09 %
Volume 942722
Vol Change -359066.00 / 27.58 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index No Significant Stability


Fundamental View of Lyra Therapeutics Inc
PE (TTM)

-119.94

Very Poor
Price / Book

99.34

Very Poor
Price / Sales

4917.47

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

19996.49 K

Enterprise Value

3077.49 K

ROA (TTM)

-55.17

Very Poor
ROE (TTM)

-82.82

Very Poor
Net Margin (TTM)

-4099.82

Very Poor
Revenue

4.40 %

1423.00 K
Net Profit

11.72 %

-61759.00 K
Debt to Equity

0.061

Excellent
Altman Z Score

-3.53

Very Poor
Quick Ratio

0

Poor
Cash Ratio

5.24

Very Good


Highs/Lows of Lyra Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.3255 0.768 % 0.513 % 0.33930.320130-May-2429-May-24
Two Week0.383 14.36 % 0.486 % 0.40.3120-May-2424-May-24
One Month5.16 93.64 % 4.80 % 5.650.3101-May-2424-May-24
Three Month5.26 93.76 % 3.56 % 6.790.3127-Mar-2424-May-24
Six Months3.31 90.09 % 15.54 % 6.790.3127-Mar-2424-May-24
One year2.57 87.24 % 26.26 % 6.790.3127-Mar-2424-May-24
Two year5.35 93.87 % 27.72 % 6.790.3127-Mar-2424-May-24


Technical View of Lyra Therapeutics Inc
RSI

13.36

Mild Bullish
MACD

-0.933

Bullish
ADX

53.05

Strong Bearish
Super Trend

0.746

Mild Bearish
Williams %R

-83.41

Mild Bullish
CCI

-42.28

Neutral


EMA 5

0.334

Mild Bearish
EMA 15

0.714

Mild Bearish
EMA 50

2.64

Mild Bearish
EMA 100

3.55

Strong Bearish
SMA 100

4.36

Strong Bearish
SMA 200

4.06

Bearish
SMA 5 / 20

0.330 / 0.550

Mild Bearish
SMA 15 / 50

0.351 / 3.49

Strong Bearish
SMA 50 / 200

3.49 / 4.06

Bearish




Charts of Lyra Therapeutics Inc


Returns of Lyra Therapeutics Inc with Peers
Period / StockLYRAINDPNVOSEVAX
1 Week0.768%1.28%108.96%-9.16%
1 Mth-93.64%9.22%70.15%-11.99%
3 Mth-93.76%7.73%66.43%1.94%
6mth-90.09%4.87%-12.50%-54.07%
1 Year-87.24%45.40%-20.45%-75.86%
2 Year-93.87%-6.32%-94.88%-81.28%
5 Years--99.43%-99.16%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Lyra Therapeutics Inc with Peers
Ratio / StockLYRAINDPNVOSEVAX
PE-119.94-1.33-1.19-3.76
P/B99.341.300.528-3.24
ROA-55.17-85.43-29.053198.22
ROE-82.82-97.78-43.980
Debt To Equity0.0610.00840.437-1.90
Revenue1423.00 K
4.40 % 		0
% 		11737.94 K
0 % 		73112.00
%
Net Income-61759.00 K
11.72 % 		-15076.47 K
5.26 % 		-33045.18 K
0 % 		-24474.00 K
5.63 %


Technicals of Lyra Therapeutics Inc with Peers
Technical / StockLYRAINDPNVOSEVAX-
ADX53.0524.4917.9115.60
CMF-0.0312-0.344-0.3410.0097
MFI38.6077.2297.5247.89
RSI13.3651.3677.7245.04
MACD Abv SignalTrueTrueTrueFalse
Price Above 50 MAFalseTrueTrueFalse-
Price Above 200 MAFalseTrueFalseFalse-


About : Lyra Therapeutics Inc

Address : 480 Arsenal Way, Watertown, MA, United States, 02472
Tel : 617 393 4600
URL : https://lyratherapeutics.com
Code : LYRA, ISIN : US55234L1052, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 01_May_2020
Employee Count : 109

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)